Security
Esperion Therapeutics, Inc. Common Stock · ESPR
ESPRNASDAQCommon stockHistorical · closed Jul 13, 2026CIK 1434868Updated Oct 6, 2026
Name history
HDL THERAPEUTICS INC · through May 7, 2008
ESPR price & chart
Historical security
This listing closed Jul 13, 2026. Live provider charts are shown only for current listings.
About the company
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
In the news
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR) ↗
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 364,020,000Source | 314,114,000Source | 221,305,000Source | 347,085,000Source | 352,319,000Source | 462,529,000Source | 324,029,000Source | 373,060,000Source | 465,886,000Source | 343,821,000Source | 205,796,000Source | 247,939,000Source |
| Property, Plant and Equipment, NetUSD | 175,000Source | 281,000Source | 6,000Source | 201,000Source | 307,000Source | 311,000Source | 228,000Source | 268,000Source | 338,000Source | 254,000Source | 0Source | 164,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 56,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 92,447,000Source | 144,717,000Source | 114,833,000Source | 86,061,000Source | 189,304,000Source | 156,158,000Source | 114,633,000Source | 226,609,000Source | 167,852,000Source | 144,761,000Source | 82,248,000Source | 124,775,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 118,980,000Source | 67,824,000Source | 42,623,000Source | 107,746,000Source | 60,360,000Source | 132,352,000Source | 81,294,000Source | 54,612,000Source | 140,190,000Source | 80,142,000Source | 48,494,000Source | 33,729,000Source |
| Inventory, NetUSD | 108,539,000Source | 80,102,000Source | 51,435,000Source | 114,466,000Source | 84,469,000Source | 104,209,000Source | 99,322,000Source | 73,095,000Source | 105,124,000Source | 94,491,000Source | 65,623,000Source | 35,201,000Source |
| Assets, CurrentUSD | 360,464,000Source | 307,555,000Source | 218,227,000Source | 342,595,000Source | 345,108,000Source | 459,461,000Source | 318,778,000Source | 365,606,000Source | 462,570,000Source | 337,998,000Source | 201,065,000Source | 246,683,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,408,000Source | 14,413,000Source | 6,287,000Source | 5,380,000Source | 10,626,000Source | 6,023,000Source | 4,815,000Source | 11,290,000Source | 4,496,000Source | 18,018,000Source | 4,507,000Source | 9,866,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,325,000Source | 6,222,000Source | 3,016,000Source | 4,233,000Source | 6,848,000Source | 2,701,000Source | 4,967,000Source | 7,130,000Source | 2,922,000Source | 5,513,000Source | 4,675,000Source | 1,036,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 815,381,000Source | 684,323,000Source | 631,309,000Source | 780,594,000Source | 696,539,000Source | 770,460,000Source | 750,240,000Source | 667,358,000Source | 767,851,000Source | 732,543,000Source | 660,790,000Source | 571,717,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 205,000Source | 195,000Source | 112,000Source | 200,000Source | 195,000Source | 257,000Source | 197,000Source | 188,000Source | 245,000Source | 196,000Source | 118,000Source | 75,000Source |
| Additional Paid in CapitalUSD | 1,288,974,000Source | 1,264,305,000Source | 1,137,822,000Source | 1,275,498,000Source | 1,260,770,000Source | 1,395,717,000Source | 1,270,074,000Source | 1,248,774,000Source | 1,376,499,000Source | 1,267,109,000Source | 1,149,170,000Source | 1,071,183,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,685,542,000Source | -1,579,711,000Source | -1,492,940,000Source | -1,654,209,000Source | -1,550,187,000Source | -1,648,907,000Source | -1,641,484,000Source | -1,488,262,000Source | -1,623,711,000Source | -1,601,029,000Source | -1,549,284,000Source | -1,340,036,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 0Source | — | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | -2,000Source |
| Stockholders' Equity Attributable to ParentUSD | -451,361,000Source | -370,209,000Source | -410,004,000Source | -433,509,000Source | -344,220,000Source | -307,931,000Source | -426,211,000Source | -294,298,000Source | -301,965,000Source | -388,722,000Source | -454,994,000Source | -323,778,000Source |
| Liabilities and EquityUSD | 364,020,000Source | 314,114,000Source | 221,305,000Source | 347,085,000Source | 352,319,000Source | 462,529,000Source | 324,029,000Source | 373,060,000Source | 465,886,000Source | 343,821,000Source | 205,796,000Source | 247,939,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 359,033,000Source | 165,873,000Source | 137,708,000Source | 298,796,000Source | 175,338,000Source | 300,359,000Source | 270,966,000Source | 164,512,000Source | 300,810,000Source | 246,233,000Source | 156,224,000Source | 92,308,000Source |
| Operating Lease, Liability, CurrentUSD | 2,384,000Source | 2,741,000Source | 918,000Source | 2,738,000Source | 2,679,000Source | 1,699,000Source | 2,822,000Source | 2,539,000Source | 2,102,000Source | 2,741,000Source | 1,553,000Source | 384,000Source |
| Accounts Payable, CurrentUSD | 77,513,000Source | 34,864,000Source | 26,214,000Source | 74,704,000Source | 47,669,000Source | 68,406,000Source | 71,994,000Source | 28,433,000Source | 65,068,000Source | 51,650,000Source | 31,718,000Source | 23,040,000Source |
| Operating Lease, Liability, NoncurrentUSD | 767,000Source | 3,299,000Source | 2,049,000Source | 1,312,000Source | 3,981,000Source | 861,000Source | 1,972,000Source | 4,416,000Source | 653,000Source | 2,570,000Source | 3,020,000Source | 665,000Source |
| Other Liabilities, NoncurrentUSD | 7,436,000Source | — | — | 7,436,000Source | — | 8,739,000Source | — | — | 8,739,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Short-term InvestmentsUSD | — | — | 0Source | — | — | — | — | — | — | — | 0Source | 42,086,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,502,000Source | 2,465,000Source | 9,870,000Source | 11,993,000Source | 11,958,000Source | 15,215,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -7,838,000Source | 1,152,000Source | 60,048,000Source | 31,648,000Source | 14,765,000Source | 10,795,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -915,000Source | 4,831,000Source | 10,633,000Source | 28,868,000Source | 30,422,000Source | 807,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,338,000Source | 27,844,000Source | 20,918,000Source | 12,432,000Source | 8,678,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -27,722,000Source | -22,628,000Source | -13,093,000Source | -23,654,000Source | -135,487,000Source | -174,827,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -189,000Source | 0Source | 0Source | -317,000Source | 42,500,000Source | 8,104,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 189,000Source | 0Source | 0Source | 317,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 16,217,000Source | -7,500,000Source | 36,184,000Source | 86,484,000Source | 50,460,000Source | 32,606,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 244,000Source | 29,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -11,694,000Source | -30,128,000Source | 23,091,000Source | 62,513,000Source | -42,527,000Source | -134,117,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 92,447,000Source | 144,717,000Source | 86,061,000Source | 189,304,000Source | 156,158,000Source | 114,633,000Source | 167,852,000Source | 144,761,000Source | 82,248,000Source | 124,775,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 16,266,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 612,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,349,000Source | 3,022,000Source | 2,669,000Source | 2,931,000Source | 2,502,000Source | 2,465,000Source | 9,870,000Source | 11,993,000Source | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 589,000Source | 699,000Source | 3,007,000Source | 1,498,000Source | 1,697,000Source | 1,621,000Source |
| DepreciationUSD | — | — | — | — | — | — | 27,000Source | 26,000Source | 105,000Source | 63,000Source | 164,000Source | 500,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | 0Source | -53,235,000Source | — | — | 0Source | -54,918,000Source | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 1,841,000Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 22,051,000Source | 15,082,000Source | 20,486,000Source | 13,723,000Source | 19,798,000Source | 19,431,000Source | 84,604,000Source | 59,251,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -31,333,000Source | -29,524,000Source | -12,725,000Source | -61,925,000Source | -25,196,000Source | -40,455,000Source | -22,682,000Source | -51,745,000Source | -209,248,000Source | -233,659,000Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | 129,224,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 97,268,000Source | 67,658,000Source | 75,290,000Source | 71,255,000Source | 86,685,000Source | 87,091,000Source | 342,862,000Source | 277,912,000Source | 271,897,000Source | 254,976,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 677,000Source | 1,584,000Source | 666,000Source | 2,454,000Source | 1,183,000Source | 1,072,000Source | 3,490,000Source | 8,022,000Source | 5,291,000Source | 2,652,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 59,897,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | — | 513,000Source | 4,448,000Source | 90,849,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 87,309,000Source | 51,632,000Source | 82,385,000Source | 73,834,000Source | 80,104,000Source | 64,995,000Source | 403,135,000Source | 332,314,000Source | 116,334,000Source | 75,475,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 41,848,000Source | 39,975,000Source | 39,509,000Source | 44,185,000Source | 43,124,000Source | 42,996,000Source | 165,786,000Source | 163,073,000Source | 142,523,000Source | 109,082,000Source |
| Operating Income (Loss)USD | — | — | -9,959,000Source | -16,026,000Source | 7,095,000Source | 2,579,000Source | -6,581,000Source | -22,096,000Source | 60,273,000Source | 54,402,000Source | -155,563,000Source | -179,501,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 677,000Source | 1,584,000Source | 666,000Source | 2,454,000Source | 1,183,000Source | 1,072,000Source | 3,490,000Source | 8,022,000Source | 5,291,000Source | 2,652,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -20,841,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 1,841,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -31,333,000Source | -29,524,000Source | -12,725,000Source | -61,925,000Source | -25,196,000Source | -40,455,000Source | -22,682,000Source | -51,745,000Source | -209,248,000Source | -233,659,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.16Source | -0.15Source | -0.06Source | -0.33Source | -0.1Source | -0.21Source | -0.11Source | -0.28Source | -2.03Source | -3.52Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.16Source | -0.15Source | -0.06Source | -0.33Source | -0.1Source | -0.21Source | -0.11Source | -0.28Source | -2.03Source | -3.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 200,736,136Source | 194,930,830Source | 197,546,239Source | 188,793,816Source | 251,353,086Source | 196,127,948Source | 207,865,080Source | 187,181,856Source | 103,106,616Source | 66,407,242Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 200,736,136Source | 194,930,830Source | 197,546,239Source | 188,793,816Source | 251,353,086Source | 196,127,948Source | 207,865,080Source | 187,181,856Source | 103,106,616Source | 66,407,242Source |
| Interest Expense (non-operating)USD | — | — | 22,051,000Source | 15,082,000Source | 20,486,000Source | 13,723,000Source | 19,798,000Source | 19,431,000Source | 84,604,000Source | 59,251,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,841,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 58,976,000Source | 56,810,000Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | 129,224,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 97,268,000Source | 67,658,000Source | 75,290,000Source | 71,255,000Source | 86,685,000Source | 87,091,000Source | 342,862,000Source | 277,912,000Source | 271,897,000Source | 254,976,000Source |
| Other Cost and Expense, OperatingUSD | — | — | 41,289,000Source | 17,286,000Source | 28,543,000Source | 15,609,000Source | 34,573,000Source | 31,538,000Source | — | 68,601,000Source | 43,267,000Source | 26,967,000Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-197125
Registration 333-201198
Registration 333-208701
Registration 333-258396
Registration 333-264303
Registration 333-286631
Filing attachments
tm2620034d3_ex4-1.htm · 8-K · 2026-07-13
EX-4.1 4 tm2620034d3_ex4-1.htm EXHIBIT 4.1 Exhibit 4.3 SECOND SUPPLEMENTAL INDENTURE This Second Supplemental Indenture (this “Supplemental Indenture”) is made and entered into as of July 13, 2026, among Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), Essence Parent Inc., a Delaware corporation (“Parent”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). RECITALS WHEREAS, the Company and the Trustee entered into an Indenture, dated Decem…
Read attachment ↗tm2613340d1_ex99-1.htm · DEFA14A · 2026-05-01
Exhibit 99.1 Esperion to be Acquired by ARCHIMED Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately $1.1 billion ANN ARBOR, Mich., May 1, 2026 (GlobeNewsWire) - Esperion Therapeutics (Nasdaq: ESPR) (“Esperion,” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardi…
Read attachment ↗tm2613340d1_ex99-1.htm · 8-K · 2026-05-01
EX-99.1 3 tm2613340d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Esperion to be Acquired by ARCHIMED Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately $1.1 billion ANN ARBOR, Mich., May 1, 2026 (GlobeNewsWire) - Esperion Therapeutics (Nasdaq: ESPR) (“Esperion,” or the “Company”), a commercial-stage biopharmaceutical company dedic…
Read attachment ↗tm2527818d4_ex99-1.htm · 8-K · 2025-10-08
EX-99.1 4 tm2527818d4_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Esperion Announces Proposed Public Offering of Common Stock October 7, 2025 ANN ARBOR, Mich., October 7, 2025 (GLOBE NEWSWIRE) - Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced that i…
Read attachment ↗tm2527818d4_ex99-2.htm · 8-K · 2025-10-08
EX-99.2 5 tm2527818d4_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Esperion Announces Pricing of Public Offering of Common Stock October 7, 2025 ANN ARBOR, Mich., October 7, 2025 (GLOBE NEWSWIRE) - Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the …
Read attachment ↗tm2527818d2_ex99-1.htm · 8-K · 2025-10-07
EX-99.1 2 tm2527818d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Esperion Corporate Presentation © 2025 Esperion Therapeutics, Inc. All rights reserved. October 2025 ─────────────────────────────────────────────────────────── 2 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This pre s e ntation c ontains forward-looking s tate me nts of Es pe rion The rape utic s, Inc. (“Es pe rion,” “we,” or “our”) that are made purs uant to the s a…
Read attachment ↗